Given that SLC15A3 regulates the inflammatory signaling of NOD2, MAVS, or STING, which are associated with inflammatory diseases (namely Crohn’s disease (84), SLE (85) and STING-associated vasculopathy with the onset of infancy (86), respectively), targeting SLC15A3 might offer the added benefit of reduced side effects. Here, SLC15A3 is linked to systemic lupus erythematosus.